Anzeige
Mehr »
Login
Donnerstag, 23.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Micro Cap & Branchenriese: Heute rein? - Partnerschaft entfacht Übernahmefantasien!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CZBW | ISIN: US44486Q1031 | Ticker-Symbol:
NASDAQ
22.01.25
21:57 Uhr
4,595 US-Dollar
0,000
0,00 %
1-Jahres-Chart
HUMACYTE INC Chart 1 Jahr
5-Tage-Chart
HUMACYTE INC 5-Tage-Chart

Aktuelle News zur HUMACYTE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiHumacyte (NASDAQ:HUMA) Given Buy Rating at D. Boral Capital2
DiHumacyte moves to test bioengineered vessel in heart surgery1
DiHumacyte, Inc: Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV for Coronary Artery Bypass Grafting1
26.12.24Humacyte (NASDAQ:HUMA) Shares Up 6% - Here's What Happened7
24.12.24Humacyte (NASDAQ:HUMA) Trading Down 3% - Time to Sell?3
HUMACYTE Aktie jetzt für 0€ handeln
23.12.24Humacyte (NASDAQ:HUMA) Sees Strong Trading Volume Following Analyst Upgrade9
23.12.24Humacyte (NASDAQ:HUMA) Price Target Raised to $17.00 at Benchmark4
20.12.24Humacyte, Inc. - 8-K, Current Report1
20.12.24Humacyte stock may fail to sustain today's gains: find out more5
20.12.24Mission Produce, Nvidia, Humacyte, BlackBerry And Other Big Stocks Moving Higher On Friday16
20.12.24Spotlight on Humacyte: Analyzing the Surge in Options Activity1
20.12.24Pre-market Movers: My Size, Nvni Group, Psyence Biomedical, Humacyte, PainReform541BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET).In the Green My Size, Inc. (MYSZ) is up over 372% at $6.43. Nvni...
► Artikel lesen
20.12.24Why Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday?4
20.12.24Humacyte-Aktie steigt um über 50% nach FDA-Zulassung12
20.12.24Humacyte stock surges over 50% on FDA approval7
20.12.24Humacyte surges on FDA approval for Symvess vascular repair product5
20.12.24DURHAM, N.C. - Die US-amerikanische Arzneimittelbehörde FDA hat Humacyte, Inc.'s SYMVESS die volle Zulassung für die Anwendung bei Erwachsenen erteilt. Das Produkt kommt zum Einsatz, wenn bei Gefäßver6
20.12.24Humacyte's SYMVESS gets FDA nod for vascular trauma3
20.12.24Humacyte, Inc: Humacyte Announces FDA Approval of SYMVESS (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma180- SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair - - In clinical testing SYMVESS was observed...
► Artikel lesen
25.11.24Humacyte (NASDAQ:HUMA) Given Buy Rating at D. Boral Capital24
Seite:  Weiter >>
80 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1